<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is associated with an increased risk of several types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and with reduced survival after <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the hypotheses that survival after a diagnosis of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid-tumor</z:e> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> is reduced in those with <z:mp ids='MP_0002055'>diabetes</z:mp> when compared with those without <z:mp ids='MP_0002055'>diabetes</z:mp>, and that treatment with <z:chebi fb="0" ids="6801">metformin</z:chebi> influences survival after <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: Data were obtained from &gt;350 U.K. primary care practices in a retrospective cohort study </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> individuals with or without <z:mp ids='MP_0002055'>diabetes</z:mp> who developed a first <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> after January 1990 were identified and records were followed to December 2009 </plain></SENT>
<SENT sid="4" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> was further stratified by treatment regimen </plain></SENT>
<SENT sid="5" pm="."><plain>Cox proportional hazards models were used to compare <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality from <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and from specific <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Of 112,408 eligible individuals, 8,392 (7.5%) had type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> mortality was increased in those with <z:mp ids='MP_0002055'>diabetes</z:mp>, compared with those without (hazard ratio 1.09 [95% CI 1.06-1.13]) </plain></SENT>
<SENT sid="8" pm="."><plain>Mortality was increased in those with breast (1.32 [1.17-1.49]) and <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> (1.19 [1.08-1.31]) but decreased in <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> (0.84 [0.77-0.92]) </plain></SENT>
<SENT sid="9" pm="."><plain>When analyzed by <z:mp ids='MP_0002055'>diabetes</z:mp> therapy, mortality was increased relative to nondiabetes in those on monotherapy with <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> (1.13 [1.05-1.21]) or insulin (1.13 [1.01-1.27]) but reduced in those on <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy (0.85 [0.78-0.93]) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: This study confirmed that type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> was associated with poorer prognosis after incident <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, but that the association varied according to <z:mp ids='MP_0002055'>diabetes</z:mp> therapy and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> site </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> was associated with survival benefit both in comparison with other treatments for <z:mp ids='MP_0002055'>diabetes</z:mp> and in comparison with a nondiabetic population </plain></SENT>
</text></document>